Epic Bio to Present Preclinical Data at 28th International Annual Congress of the World Muscle Society SOUTH SAN FRANCISCO, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...

Epic Bio to Present at Upcoming BMO Biopharma Spotlight Series Event SOUTH SAN FRANCISCO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...

Epic Bio Presents Compelling Preclinical Data Supporting Clinical Initiation of EPI-321 for FSHD - NHP studies demonstrate EPI-321’s favorable safety and pharmacokinetic profile - - IND and CTA applications planned for 2023 - SOUTH SAN FRANCISCO, Calif., June 16, 2023 (GLOBE NEWSWIRE) --...

Epic Bio to Present Preclinical Data at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting SOUTH SAN FRANCISCO, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Epic BIO, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...

SOLVE FSHD Invests in Epic Bio to Advance Potentially Curative Therapy SOUTH SAN FRANCISCO, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...